Vitamin D Deficiency Clinical Trial
Official title:
Effect of Vitamin D3 Supplementation Over 25-hydroxivitamin D (25-OH-D) Status in Children From 12-30 Months of Age: Randomized Clinical Trial
Background Vitamin D (VD) is essential for calcium absorption, bone health and growth in
children. In a national representative sample authors found mean serum concentration of
25-Hydroxi-Vitamin-D (25-OH-D) of 59 nmol/L, in children < 5 y of age. Prevalence deficiency
of VD under 50 nmol/L was 33%, which means that 3 million preschool- age children have VD
deficiency in Mexico. Additionally, less than 3% of the children use supplements with VD.
Objective To assess the effect of 400UI, 800IU of vitamin D2 and 1000IU of vitamin
D3-colecalciferol- over 25-Hidroxi Vitamin D (25-OH-D) status and a multiple vitamin
supplementation per day as a control group in children from 12-30 months of age in
Cuernavaca, Morelos in a 4 month period.
Methods Randomized double blind parallel clinical trial, with vitamin D3 (colecalciferol)
supplementation in 220 children from 12 - 30 months who attend day care centers.
Three supplementations will be given to children: 400IU and 800IU of vitamin D2, the third
group 1000IU of D3-colecalciferol- and the control group will receive a multi vitamin
supplementation. The duration of the intervention will be 16 weeks. Blood measurements would
be taken at baseline, and at 16 weeks.
This study compares the efficacy of three dose of VD in children from 12-30 months of age,
over the nutritional status of 25 hydroxivitamin D (25-OH-D). This intervention is of
importance to establish supplementation strategies to prevent VD deficiency in Mexico.
Keywords: Vitamin D, nutritional deficiencies, micronutrients, children, México.
2. Objective. To assess the effect of 400UI, 800IU of vitamin D2 and 1000IU of vitamin
D3-colecalciferol- over 25-Hidroxi Vitamin D (25-OH-D) status and a multiple vitamin
supplementation per day as a control group in children from 12-30 months of age in
Cuernavaca, Morelos in a 4 month period.
3. Hypothesis Supplementation with 1,000 IU/d of vitamin D3-colecalciferol will have a
greater effect on 25-OH-D concentrations compared to a dose of 400 IU and 800IU per day of
vitamin D2 and will be more effective to decrease vitamin D deficiency in children from 12-30
months of age 4. Methods. 4.1 Study design. Factorial randomized double blind, parallel,
controlled clinical trial with administration of a supplement containing 400IU or 800 IU of
D2 or 1,000 IU of vitamin D3 -colecalciferol- and a multiple vitamin supplementation per day
as a control group during a 4 month period.
Participants: A total of 220 children, both sexes, from 12-30 month of age will be studied
(55 per treatment group).
Intervention period: 4 months Project duration: 18 months Place: Day Care centers(SEDESOL) in
Cuernavaca, Morelos 4.2. Treatment: The Moses Oakford method will be used to assign the
treatment. The scheme to randomize the sample will be by stratification and in blocks using a
list of random numbers generated by a computer (STATA13). Stratification will be by age
groups 12-18 months, 19-24 months and 25-30 months. Treatment will be assigned randomly to
each supplement group. One group will receive 400IU of vitamin D2, the second group will
receive 800 IU of D2, the third group will receive 1000IU of D3-colecalciferol- and the
control group will receive a multi vitamin supplementation, that contains iron, vitamin A, C.
E folic acid, niacin, and vitamins B1, B2, B6 y B12 The duration of the intervention will be
16 weeks.
4.3. Study Population- Children between 12 and 30 months of age, both sexes, which attend day
care centers that are part of a national government program which main objective is to
support working mothers and those who intend to work and do not have access to a health
service. The program also includes single parents in charge of their family. Sample will be
by convenience until sample is completed. Day care will be selected by convenience,
(Principal interested in participating in the research project). A reunion will be made with
authorities from SEDESOL and with the principals of the day care centers. The study
objective, methodology and the importance of the project will be explained. After the
meeting, a list of the day care centers who wish to participate will be made. A meeting with
the parents will be assigned in order to explain the purpose, importance, objective and
methods of the project.
Inclusion Criteria. Children- from 12-30 months of age, both sexes who attend SEDESOL day
care centers in Cuernavaca, and whose parents agree to participated and sign the informed
consent.
Exclusion Criteria. Chronic disease, anemia (Hb<9.0), does not want to participate, receiving
vitamin D supplementation or other supplement in the last 6 months.
4.4. Sample size and statistical power. Up to date, efficacy studies on vitamin D
supplementation in preschool-age children are scarce. Three studies were considered: The
sample size of these studies have been around 100-150 children in total.
The first study supplemented preschool-age children with 400IU of vitamin D for 4 months,
having found a positive difference on the supplemented group of 23 nmol/L of 25-OH-D in
relation with the placebo group. The second study was carried out with infants, the aim of
the study was to test the efficacy, dose response of various international units of vitamin
D: 400, 800, 1,200 and 1,600 per day with a follow up of 12 months. The increase in serum
levels of 25-OH-D were: 18, 42, 74 y 120 nmol/L, respectively. On the other hand, other study
supplemented children between 2 weeks and 3 months of age with various doses of vitamin D
daily for 3 months: 400, 1,200 ó 1,600 IU/d. The increases observed in serum levels of
25-OH-D in this study were: de 14, 37.5 y 66.5 nmol/L, respectively.
Considering these studies, and the serum levels of 25-OH-D observed in our study in the same
population during 2012(41-50 nmol/L), it is expected to observe an increase around 20 nmol/L
in children receiving 400 IU/d and de 40 nmol/L in children receiving 1,000 IU/d of VD.
The size and power of the sample was calculated considering a basal level of serum 25-OH-D of
41 a 50 nmol/L with an increase of 20-40 nmol/L with a S.D of 20 a 40 nmol/L. As a result, a
sample size of 100 children per group were obtained. With this sample a mean difference of 10
nmol/L can be obtained with a power of 80% α<0.05-two tails- 4.5. Variables. Outcome
variables. Measurements will be taken at base line and at 16 weeks: serum 25-OH-D,
parathyroid hormone (PTH) and hemoglobin.
Other variables. Anthropometry: Anthropometric measurements such as: weight, height/length,
head circumference and mid upper arm will be taken. Measurements will be taken by trained and
standardized personnel using standard technics according to protocols. Measurements will be
taken at baseline and at 16wk. Weight, height/length and circumferences will be transformed
to Z scores by using the Anthro WHO program.
Diet: Dietary information will be obtained by a food frequency questionnaire (FFQ) and a 24-h
recall. Both dietary questionnaires will be administered by trained personnel to the
mother/care taker. Dates will be set with mothers in these two momentums to obtain dietary
information. Dietary information will be taken at baseline and at 16wks.
Morbidity: Morbidity data will be collected daily at each day care center by trained
personnel. A checklist will be used to record symptoms of diarrhea and acute respiratory
infections. Mothers or caretakers will be asked to recall any symptoms.
Sociodemographic Characteristics: Information about the participant's household's
characteristics, the education level and parents occupation will be obtained by interviewing
of the mother. An indicator of household conditions will be calculated by principal component
analysis.
Infant Development:
A screening test will be applied to assess and identified children at risk. This test is
called in spanish "Prueba Evaluacion Desarrollo Infantil" (EDI).
4.6 Statistical Analysis. The effect of the intervention over the final serum concentrations
of 25-OH-D will be evaluated through a t test for median differences. If the variables do not
have a normal distribution, will be transformed. If important differences are found at the
beginning of the study between treatment groups, a multiple linear regression will be made to
control for confounding variables.
4.7. Study Stages and Data Collection. 4.7.1 Recruitment Recruitment and follow-up of
children will be made at the day-care centers (SEDESOL) in Cuernavaca, Morelos. A date will
be established at each day care center to explain to mothers the study objective and
procedures: anthropometric, biochemical, diet, socioeconomic questionnaire, randomization and
treatment. A consent form will be read to each parent and signed if accept to participate.
Doubts will be cleared at the meeting with parents.
4.7.2 Baseline Anthropometric measurements will be taken: Weight, length/height, head and mid
upper arm circumferences. During the first visit capillary blood samples will be taken in
situ to measure hemoglobin concentrations (Hb) by a spectrophotometer Hemocue®. According to
selection criteria if a child has <9.0g/dl, the child will be referred to the nearest health
center. A vein blood sample (5mL) will be taken to determine serum concentrations of 25-OH-D
y PTH. The sample will be obtained by a Pediatrician Nurse with experience. A
sosciodemographic questionnaire will be applied to obtain information on household,
education, marital status and income. In this first visit, children will be randomly assigned
to the treatment. All interviews and measurements will be taken by trained and standardized
personnel.
4.7.3 Intervention: Treatment will be administered according to randomization: 400IU/d,
800IU/d, 1000 IU/d and a multivitamin. Two standardized and trained personnel will be present
each day at each day care center. With a list of the names of the participants in hand each
child will be called to receive the assigned treatment. Every day at 7:00 a.m. children will
receive the treatment.
4.7.4 Adverse effects: The maximum dose -1,000 IU/d- it's under the upper level UL, according
to the recommendations of the Institute of Medicine (IOM) for children between 12 and 36
months of age. By definition the "Upper Level" it's considered a safe intake by the IOM
expert comity therefore, adverse effects associated with 1,000 IU7d will not be observed for
prolonged periods at this age group.
4.7.5 Toxicity Monitoring: Every day at 7:30 a.m. a trained nutritional student will be
gathering morbidity information and adverse effects. The adverse effects associated with
excessive intake of vitamin D are: dehydration, nausea, vomiting, conscious alterations and
high calcium excretion. If symptoms were to appear, a medical pediatrician will monitor and
follow the child. High calcium excretion it is only observed in severe intoxication with
vitamin D.
If adverse effects were to appear in the study population, the researchers responsible of the
study will stop the study and report adverse effects.
4.7.6 Committee experts on adverse effects: The committee experts will be held by Dr.
Patricia Clark and Dr. María Dolores Ramirez. Assessment of adverse effects will be held at
the National Institute of Public Health in Cuernavaca, Morelos, Mexico.
4.7.7 Final Assessment A meeting will be held with each mother at each day care center to
obtain information on child´s diet. A 24 Hour recall and a Frequency Food Questionnaire will
be applied to the mother. The last assessment will be at 16 weeks. Anthropometric
measurements will be taken: Weight, length/height, head and mid upper arm circumferences.
Blood Samples Capillary blood samples will be obtained by finger prick and measured in a
Portable Photometer Hemocue. Venous blood samples (5ml) will be drawn from antecubital vein
at baseline at 16wks. Samples will be obtained by a trained Pediatrician Nurse who has
previews experience working with children.
5. Ethical considerations: Written Informed consent will be obtained and signed by both
parents. The study protocol is approved by the Ethics, Research and Biosecurity Committee of
the National Institute of Public Health.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 |